Nasdaq btai.

The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 dated October 31, 2023.

Nasdaq btai. Things To Know About Nasdaq btai.

Marpai, Inc. Class A Common Stock (MRAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.NEW HAVEN, Conn., Dec. 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 dated October 31, 2023. Over the past 3 months, 10 analysts have published their opinion on BioXcel Therapeutics (NASDAQ:BTAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for BTAI stock stock is $12.2, which predicts an increase of 213.62%. The lowest target is $4.00 and the highest is $22. …

Investors, who purchased BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares prior to December 2021 and continue to hold any of those NASDAQ: BTAI shares, also have certain options and should contact ...BioXcel Therapeutics ( BTAI 2.61%) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ...Find the latest on option chains for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

14 Aug 2023 ... BioXcel Therapeutics (BTAI 2.37%) stock is plummeting Monday. The clinical ... NASDAQ: BTAI. BioXcel Therapeutics. Today's Change. (2.37%) $0.09.BioXcel Therapeutics (NASDAQ:BTAI), a biopharma company based in Connecticut, leverages AI and machine learning to develop innovative treatments for central nervous system and immuno-oncology ...

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Commercial Day Highlights Positive Early Launch Metrics for IGALMI™ On October 18, 2022, BioXcel Therapeutics ...Fintel reports that on June 30, 2023, Mizuho reiterated coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation.. Analyst Price Forecast Suggests 205.94% Upside. As of June 2 ...NEW HAVEN, Conn., May 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ...

NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...

BioXcel Therapeutics, Inc. Common Stock (BTAI) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.

Source: aslysun / Shutterstock.com. BioXcel Therapeutics (NASDAQ:BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space.Based on its “about us” page, BioXcel is ...BioXcel Therapeutics (NASDAQ:BTAI) stock is rocketing higher on Wednesday after the biopharmaceutical company announced results from an audit of its Tranquility II clinical trial.. According to a ...Allogene Therapeutics (NASDAQ:) is a clinical-stage biotech firm specializing in developing allogeneic T cell cancer treatment therapies. Around 67.4% of ALLO’s share count consists of publicly ...AI. BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.NEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...BioXcel Therapeutics Inc Follow Share $3.93 After Hours: $3.90 (0.76%) -0.030 Closed: Nov 24, 4:39:38 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Ardelyx Inc …

NEW HAVEN, Conn., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...BioXcel Therapeutics ( NASDAQ: BTAI) is a biopharmaceutical firm located in Connecticut, United States. The company's objective is to market and develop therapies for the treatment of central ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary ...

BTAI BTAI AFTER HOURS QUOTE BTAI LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ... Real time BioXcel Therapeutics (BTAI) stock price quote, stock graph, news & analysis.

Nov 30, 2023 · The public float for BTAI is 20.22M, and currently, short sellers hold a 25.11% ratio of that floaft. The average trading volume of BTAI on November 30, 2023 was 3.17M shares. BTAI) stock’s latest price update. BioXcel Therapeutics Inc (NASDAQ: BTAI)’s stock price has dropped by -0.26 in relation to previous closing price of 3.91. One share of BTAI stock can currently be purchased for approximately $3.89. Is BioXcel Therapeutics, Inc. listed on the NASDAQ or NYSE?BTAI BTAI AFTER HOURS QUOTE BTAI LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ... Philadelphia, Pennsylvania--(Newsfile Corp. - November 29, 2023) - A recently filed securities fraud class action complaint alleges that BioXcel Therapeutics Inc. (NASDAQ: BTAI), via certain ...Nov 30, 2023 · The latest price target for BioXcel Therapeutics ( NASDAQ: BTAI) was reported by HC Wainwright & Co. on Wednesday, November 15, 2023. The analyst firm set a price target for 11.00 expecting BTAI ... See the latest BioXcel Therapeutics Inc stock price (BTAI:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ...

Mar 9, 2023 · BioXcel Therapeutics will host a conference call and webcast at 8:30 a.m. ET on March 9 to discuss its fourth quarter and full-year 2022 financial results and provide an update on recent ...

Based on analysts offering 12 month price targets for BTAI in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

(NASDAQ: BTAI) Bioxcel Therapeutics's forecast annual revenue growth rate of 118.87% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.69%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.54%. According to the issued ratings of 7 analysts in the last year, the consensus rating for BioXcel Therapeutics stock is Hold based on the current 5 hold ratings and 2 buy ratings for BTAI. The average twelve-month price prediction for BioXcel Therapeutics is $23.88 with a high price target of $40.00 and a low price target of $11.00.NEW HAVEN, Conn., Aug. 14, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...NEW HAVEN, Conn., Jan. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...Find the latest on short interest for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.BioXcel Therapeutics Stock (NASDAQ:BTAI), Short Interest Report. Short interest for BioXcel Therapeutics gives investors a sense of the degree to which investors are betting on the decline of ... BioXcel Therapeutics (Nasdaq:BTAI) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech BioXcel Therapeutics …Nov 29, 2023 · According to the issued ratings of 7 analysts in the last year, the consensus rating for BioXcel Therapeutics stock is Hold based on the current 5 hold ratings and 2 buy ratings for BTAI. The average twelve-month price prediction for BioXcel Therapeutics is $23.88 with a high price target of $40.00 and a low price target of $11.00. The big shareholder groups in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely ...For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. Hagens Berman is a global plaintiffs’ rights complex litigation law firm focusing on corporate accountability ...

BioXcel just announced a big change. Keith Noonan BioXcel Therapeutics (NASDAQ:BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share ...Isaac Mitchell. November 25, 2023. Technologies. BioXcel Therapeutics Inc (NASDAQ:BTAI)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 0.78. At the close of trading, the stock’s price was $4.00, to imply an increase of 4.44% or $0.17 in intraday trading. The BTAI share’s 52-week high ...If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...Instagram:https://instagram. mfs value r6lucid diagnostics stockbuy or sell disney stockhow to get started trading futures NEW HAVEN, Conn., May 25, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ... best workers' comp insurance californiatrade the pool SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI. NEW YORK , Aug. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI). Such investors are … tjx corporation NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ...